Marc Engelen (Pediatric) neurology, Amsterdam UMC) received a Vidi grant from NOW. This grant of 800,000 Euro enables researchers to establish a new innovative research line.
The Vidi grant will enable the ALD research group to develop new surrogate outcome measures for clinical trials in adrenoleukodystrophy and possibly other neurodegenerative diseases affecting the spinal cord. Specifically, quantitative MRI (DTI, MTI, NODDI), optical coherence tomography and force
plate analysis of locomotion are promising candidates. Furthermore, by using the PEROX biobank linked to the patient cohort we will search for biomarkers that predict disease severity and progression. For this, we will analyze plasma and CSF with lipidomics and other techniques.